

Involvement of Multidrug Resistance-Associated Protein 4 in Efflux Transport of Prostaglandin E₂ across Mouse Blood-Brain Barrier and Its Inhibition by Intravenous Administration of Cephalosporins

Shin-ichi Akanuma, Ken-ichi Hosoya, Shingo Ito, Masanori Tachikawa, Tetsuya Terasaki, and Sumio Ohtsuki

Department of Pharmaceutics, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan (S.A., K.H., M.T.); and Division of Membrane Transport and Drug Targeting, Graduate School of Pharmaceutical Sciences, Tohoku University, Aoba-ku, Sendai, Miyagi, Japan (S.I., T.T., S.O.)

Received December 28, 2009; accepted February 26, 2010

ABSTRACT

Prostaglandin E₂ (PGE₂) acts as a modulator of synaptic signaling and excitability in the brain. Because PGE₂ is barely inactivated enzymatically in adult brain, its brain level is considered to be controlled by efflux transport across the blood-brain barrier (BBB). The purpose of the present study was to clarify the efflux transport of PGE₂ at the BBB and the interaction of various drugs with this process. [³H]PGE₂ was eliminated from brain across the BBB with a half-life of 16.3 min, and the elimination was inhibited by 3 mM unlabeled PGE₂. Multidrug resistance-associated protein 4 (MRP4/ABCC4) was reported to be localized at the luminal membrane of the BBB. MRP4-expressing membrane vesicles showed significant uptake of [³H]PGE₂ and the uptake was inhibited by cefmetazole

with an IC₅₀ value of 10.2 μM. At the concentration of 20 μM, several drugs, including cefazolin, cefotaxime, ceftriaxone, and ketoprofen, significantly inhibited [³H]PGE₂ uptake into MRP4-expressing membrane vesicles. Using the brain efflux index method, preadministration of cefmetazole, cefazolin, ceftriaxone, and cefotaxime was found to inhibit [³H]PGE₂ efflux from brain across the BBB. Furthermore, intravenous administration of the cefmetazole dose dependently reduced [³H]PGE₂ elimination across the BBB (ID₅₀ = 120 mg/kg). These results indicate that PGE₂ is eliminated from the brain by MRP4-mediated efflux transport at the BBB, and peripheral administration of cefmetazole decreases the efflux transport of PGE₂ at the BBB; this interaction may influence brain function.

Prostaglandin E₂ (PGE₂) is a main product of the cyclooxygenase (COX) pathway. Two COX isoenzymes, COX-1 and COX-2, convert arachidonic acid released by phospholipases A₂ to prostaglandin H₂, which in turn is metabolized by terminal prostaglandin E synthase (PGES) into PGE₂ (Ivanov and Romanovsky, 2004). In the brain, COX-2 is constitutively expressed in various neuronal cells, especially in

hippocampal and cortical glutamatergic neurons (Ikeda-Matsuo et al., 2005). PGE₂ in the brain acts as a modulator of synaptic signaling and excitability, both physiologically and pathologically (Chen and Bazan, 2005). In addition, COX-2 and PGES are up-regulated by inflammatory stimuli and specifically induce fever via hypothalamic E-type prostanoid receptor activation (Sugimoto and Narumiya, 2007). Thus, PGE₂ in the brain plays an important role in the modulation of neuronal signaling and neuroinflammatory responses.

The level and thus the biological activity of PGE₂ are controlled by the balance between synthesis and inactivation of PGE₂ in each organ. In peripheral organs, the first step of the inactivation process is mediated by NAD⁺-dependent 15-hydroxyprostaglandin dehydrogenase. Although COX-2 and PGES-positive neuronal and glial cells exist in the brain, NAD⁺-dependent 15-hydroxyprostaglandin dehydrogenase

This study was supported by the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT) and the Japan Society for the Promotion of Science (JSPS) [Grants-in-Aid for Young Scientists (Start-up) KAKENHI 20890079, Young Scientists (B) KAKENHI 20790127, and Scientific Research (B) KAKENHI 21390042]; and the Industrial Technology Research Grant Program from New Energy and Industrial Technology Development Organization (NEDO) of Japan.

Article, publication date, and citation information can be found at <http://jpet.aspetjournals.org>.
doi:10.1124/jpet.109.165332.

ABBREVIATIONS: PGE₂, prostaglandin E₂; COX, cyclooxygenase; PGES, prostaglandin E synthase; BBB, blood-brain barrier; BCEC, brain capillary endothelial cell; Oat3, organic anion transporter 3; Pgt, prostaglandin transporter; MRP, multidrug resistance-associated protein; Oatp1a4, organic anion transporting polypeptide 1a4; NSAIDs, nonsteroidal anti-inflammatory drugs; BEI, brain efflux index; DMSO, dimethyl sulfoxide; ECF, extracellular fluid; S2, secondary somatosensory cortex; HPLC, high-performance liquid chromatography.

activity is barely detectable in cerebral cortex of adult brain (Nakano et al., 1972; Alix et al., 2008). Therefore, PGE₂ may be eliminated through a brain-to-blood efflux process at the blood-brain barrier (BBB) to control its level in the brain.

The BBB is formed by tight junctions of brain capillary endothelial cells (BCECs). PGE₂ (pK_a = ~5) exists predominantly in charged form at physiological pH and cannot easily cross the BBB by passive diffusion. Although it is still not known whether PGE₂ in the brain is eliminated via a carrier-mediated process at the BBB, it was reported that PGE₂ is transported by organic anion transporters, such as organic anion transporter 3 (Oat3/*SLC22A8*), prostaglandin transporter (Pgt/*SLCO2A1*), and multidrug resistance-associated protein 4 (MRP4/*ABCC4*) (Kimura et al., 2002; Reid et al., 2003; Kobayashi et al., 2004). It has also been shown that organic anion transporting polypeptide 1a4 (Oatp1a4/*SLCO1A4*), Oat3, and/or MRP4 are involved in brain-to-blood efflux transport at the BBB (Leggas et al., 2004; Ohtsuki and Terasaki, 2007). Therefore, these transporters are likely to be involved in the brain-to-blood efflux transport of PGE₂ at the BBB.

Cephalosporins and nonsteroidal anti-inflammatory drugs (NSAIDs) are used to treat numerous infectious diseases and to suppress autoimmune responses such as fever (Molavi, 1991; Kim et al., 2009) but have adverse effects such as inhibitory neuronal signal attenuation and encephalitis (Schliamser et al., 1991; Sunden et al., 2003). These drugs are substrates or inhibitors for organic anion transporters, including Oat3 and MRP4 (El-Sheikh et al., 2007; Nozaki et al., 2007). Because PGE₂ is also related to these central nervous system symptoms (Phillis et al., 2006), it was hypothesized that PGE₂ elimination across the BBB might be inhibited by the above drugs, resulting in alterations of brain function through increased brain levels of PGE₂.

The purpose of this study was to elucidate the mechanism of PGE₂ elimination from brain across the BBB by using the brain efflux index (BEI) method in mice and to evaluate the effect of various drugs on in vitro MRP4-mediated PGE₂ transport and in vivo PGE₂ elimination from brain across the BBB.

Materials and Methods

Animals. Adult male C57BL/6J mice (20–30 g) were purchased from Japan SLC (Hamamatsu, Japan). All experiments conformed to the provisions of the Animal Care Committee, University of Toyama, and were approved by the Animal Care Committee, Graduate School of Pharmaceutical Sciences, Tohoku University.

Reagents. [5,6,8,11,12,14,15-³H(N)]-Prostaglandin E₂ (³H]PGE₂) (185.6 Ci/mmol) was purchased from PerkinElmer Life and Analytical Sciences (Waltham, MA). [carboxyl-¹⁴C]Inulin (¹⁴C]inulin; 1.9 mCi/g) was purchased from Moravik Biochemicals (Brea, CA). Amphotericin B, ampicillin, clarithromycin, dimethyl sulfoxide (DMSO), dipyridamole, fluconazole, itraconazole, kanamycin sulfate, mefenamic acid, meloxicam, miconazole, salicylic acid, sulpyrine monohydrate, sodium taurocholate, and vancomycin hydrochloride were obtained from Wako Pure Chemicals (Osaka, Japan). Acetaminophen, cefaclor, cefazolin sodium salt, cefmetazole sodium salt, cefotaxime sodium salt, cefsulodin sodium salt hydrate, ceftriaxone disodium salt, cephalixin hydrate, diclofenac, ibuprofen, indomethacin, loxoprofen, sodium salt, ketoprofen, minocycline hydrochloride, and ursodeoxycholic acid were obtained from Sigma-Aldrich (St. Louis, MO). Cefotiam was purchased from the USP (Rockville, MD). Cefdinir and celecoxib were purchased from Toronto Research Chem-

icals Inc. (North York, ON, Canada). Control vesicles and human MRP4-expressing Sf9 membrane vesicles were purchased from GenoMembrane (Yokohama, Japan). All other chemicals were commercial reagent grade products.

Transport Studies with MRP4-Expressing Membrane Vesicles. Control vesicles and MRP4-expressing membrane vesicles were derived from insect Sf9 cells. Uptake experiments were performed using the rapid filtration technique as described previously, with minor modifications (Reid et al., 2003; Uchida et al., 2007). In brief, experiments were performed in medium containing 5 μg of membrane vesicles, 0.25 M sucrose, 10 mM Tris-HCl (pH 7.4), 10 mM MgCl₂, 4 mM ATP, 10 mM phosphocreatine, 100 μg/ml creatine phosphokinase, and 0.2 μCi [³H]PGE₂ with or without inhibitor at the indicated concentration in a total volume of 55 μl. The reactions were performed at 37°C and stopped by addition of 400 μl of ice-cold stop solution [0.25 M sucrose, 10 mM Tris-HCl (pH 7.4), and 100 mM NaCl]. The samples were immediately passed through 0.45-μm MF-Millipore membrane filters (Millipore Corporation, Billerica, MA) under vacuum. The filters were washed three times with 3 ml of ice-cold stop solution. The radioactivity derived from the [³H]PGE₂ that was retained on the filter was determined by liquid scintillation counting using ACSII (GE Healthcare, Little Chalfont, Buckinghamshire, UK). The protein content was determined with a DC Protein Assay Kit (Bio-Rad Laboratories, Hercules, CA), with bovine serum albumin as a standard. The uptake value was expressed as the vesicle/medium ratio calculated by dividing the amount taken up into the membrane vesicles by the substrate concentration in the uptake medium. The median inhibitory concentration (IC₅₀) value of cefmetazole was estimated from eq. 1, using the nonlinear least-squares regression analysis program MULTI:

$$v = V_{\min} + (V_{\max} - V_{\min})/[1 + ([I]/IC_{50})^n] \quad (1)$$

where v , V_{\min} , V_{\max} , $[I]$, and n are the uptake rate, the minimum uptake rate, the maximum uptake rate, the concentration of cefmetazole, and the Hill constant, respectively.

PGE₂ Efflux Studies from Brain across the BBB Using BEI Method in Mice. In vivo mouse brain elimination experiments were performed using the intracerebral microinjection technique (Akanuma et al., 2008). In brief, a C57BL/6J mouse was anesthetized by intraperitoneal administration of pentobarbital (50 mg/kg b.wt.) and placed in a stereotaxic frame (SR-5M; Narishige, Tokyo, Japan). The applied solution, consisting of [³H]PGE₂ (96 nCi) and [¹⁴C]inulin (4.8 nCi) dissolved in 0.3 μl of extracellular fluid (ECF) buffer (122 mM NaCl, 25 mM NaHCO₃, 3 mM KCl, 1.4 mM CaCl₂, 1.2 mM MgSO₄, 0.4 mM K₂HPO₄, 10 mM D-glucose, and 10 mM HEPES, pH 7.4) with 0.1% ethanol in the presence or absence of unlabeled compounds, was administered into the secondary somatosensory cortex (S2) region of the brain. The needle was left in the injection configuration for an additional 4 min to prevent reflux of the injected solution along the injection track, before being slowly retracted. [¹⁴C]Inulin is an impermeable marker used to normalize the actual injection volume, because the injection volume is small (0.3 μl). In a preadministration study, the inhibitor solution (10 μl) at the indicated concentration in ECF buffer with or without 0.25% DMSO was injected into the S2 region 5 min before administration of the applied solution. As a control, ECF buffer with or without 0.25% DMSO was injected. In an intravenous administration study, 200 μl of the Ringer-HEPES buffer (141 mM NaCl, 4 mM KCl, 2.8 mM CaCl₂, and 10 mM HEPES-NaOH, pH 7.4) containing each compound was injected into the jugular vein 15 min before administration of the applied solution. At a designated time, the mouse was decapitated, and the left and right cerebrum and cerebellum were excised. Each tissue was dissolved in 2 ml of 2 N NaOH at 55°C for 3 h and then mixed with 14 ml of Hionic-Fluor (PerkinElmer Life and Analytical Sciences). The radioactivity was measured in a liquid scintillation counter equipped with an appropriate crossover correction for ³H and ¹⁴C (LSC-5100; Aloka, Tokyo, Japan).

The BEI value was defined according to eq. 2, and the percentage of [^3H]PGE $_2$ remaining in the ipsilateral cerebrum ($100 - \text{BEI}$) was determined using eq. 3 (Kakee et al., 1996):

$$\text{BEI}(\%) = \frac{\text{Test substrate undergoing efflux at the BBB}}{\text{Test substrate injected into the brain}} \times 100 \quad (2)$$

$$100 - \text{BEI}(\%)$$

$$= \frac{\text{(Amount of } [^3\text{H}]\text{PGE}_2 \text{ in the brain/ amount of } [^{14}\text{C}]\text{inulin in the brain)}}{\text{(Concentration of } [^3\text{H}]\text{PGE}_2 \text{ in injectate/ concentration of } [^{14}\text{C}]\text{inulin in injectate)}} \times 100 \quad (3)$$

The apparent elimination rate constant (k_{eff}) was determined by fitting a semilogarithmic plot of $100 - \text{BEI}$, i.e., the percentage remaining in the ipsilateral cerebrum, versus time, using the non-linear least-squares regression analysis program MULTI. To evaluate the inhibitory effect on [^3H]PGE $_2$ efflux across the BBB, the BEI value of [^3H]PGE $_2$ at 40 min was determined in the presence or absence of various drugs.

The median inhibitory dose (ID_{50}) of cefmetazole was obtained from eq. 4, using the nonlinear least-squares regression analysis program MULTI:

$$\text{BEI} = \text{BEI}_{\text{min}} + (\text{BEI}_{\text{max}} - \text{BEI}_{\text{min}}) / [1 + (I/\text{ID}_{50})^n] \quad (4)$$

where BEI_{min} , BEI_{max} , I , and n are the minimum of BEI, the maximum of BEI, the intravenous dose of cefmetazole, and the Hill constant, respectively.

HPLC Analysis. To examine ^3H -labeled compounds in the plasma and brain after microinjection, 1 μCi of [^3H]PGE $_2$ was administered to the S2 region of mouse brain. At 5 min after administration of [^3H]PGE $_2$, blood was collected via the jugular vein. Immediately thereafter, the mouse was decapitated, and the ipsilateral cerebrum was obtained. Plasma was obtained by centrifugation at 7800g for 5 min at 4°C. For deproteinization, 250 μl of plasma was mixed with 1.0 ml of ethanol. The mixture was centrifuged at 15,000g for 20 min at 4°C, and the supernatant was collected. The brain sample was homogenized in 10 volumes of ethanol. The homogenate was centrifuged at 15,000g for 20 min at 4°C, and the supernatant was collected. Each sample was dried under nitrogen. The residue was dissolved in 25 μl of the mobile phase (acetonitrile-acetic acid-water, 45:0.1:55, v/v/v). Then, 20 μl was subjected to HPLC analysis according to a previously reported method (Eguchi et al., 1992; Alix et al., 2008). The HPLC system consisted of a pump (EP-300; Eicom, Kyoto, Japan), a column oven (ATC-300; Eicom), and a UV monitor (NOD-10; Eicom). The HPLC analytical column was an Inertsil ODS-2 column (5 μm , 4.6 \times 150 mm; GL Sciences, Tokyo, Japan). The mobile phase was pumped through the column at a rate of 1.0 ml/min at 20°C. Samples of eluate were collected in scintillation counting vials, and the ^3H radioactivity in each fraction (1.0 ml) was determined in a liquid scintillation counter (LSC-5200; Aloka).

Data Analysis. Unless otherwise indicated, all data represent the mean \pm S.E.M. The parameters determined by the least-squares regression analysis (k_{eff} , IC_{50} , and ID_{50}) are presented as the mean \pm S.D. Statistical significance of differences between the means was determined by using the unpaired two-tailed Student's t test for two groups and by one-way analysis of variance followed by Dunnett's test for more than two groups.

Results

Efflux Transport of [^3H]PGE $_2$ in the Cerebral Cortex across the BBB. Figure 1A shows the time profile of the percentage of [^3H]PGE $_2$ remaining in the ipsilateral cerebrum after microinjection into the S2 region of the mouse brain. The percentage of [^3H]PGE $_2$ remaining decreased in a




Fig. 1. In vivo efflux transport of [^3H]PGE $_2$ from mouse brain across the BBB. A, time course of [^3H]PGE $_2$ in the ipsilateral cerebrum after intracerebral microinjection in the presence of [^{14}C]inulin as an internal reference. A mixture of [^3H]PGE $_2$ (96 nCi) and [^{14}C]inulin (4.8 nCi) dissolved in 0.3 μl of ECF buffer containing 0.1% ethanol was injected into the S2 region of mouse brain. Each point represents the mean \pm S.E.M. ($n = 4-5$). B, self-inhibitory effect of unlabeled PGE $_2$ on the percentage of [^3H]PGE $_2$ remaining in the ipsilateral cerebrum at 40 min after intracerebral microinjection. A mixture of [^3H]PGE $_2$ and [^{14}C]inulin dissolved in 0.3 μl of ECF buffer containing 3 mM PGE $_2$ was injected. Each column represents the mean \pm S.E.M. ($n = 3-4$). **, $p < 0.01$, significantly different from the control.

time-dependent manner, indicating that [^3H]PGE $_2$ was eliminated from mouse brain. The apparent efflux rate constant across the BBB (k_{eff}) of [^3H]PGE $_2$ calculated from the slope was $4.23 \times 10^{-2} \pm 0.27 \times 10^{-2} \text{ min}^{-1}$ (mean \pm S.D.). No radioactivity associated with this efflux transport process was detected in the contralateral cerebrum or cerebellum (data not shown). In addition, the percentage of [^3H]PGE $_2$ remaining in the brain at 40 min after microinjection was increased by coadministration of 3 mM unlabeled PGE $_2$ (Fig. 1B). Figure 2 shows typical HPLC chromatograms of ^3H radioactivity in the injectate (Fig. 2A), ipsilateral cerebrum (Fig. 2B), and jugular venous plasma (Fig. 2C) at 5 min after intracerebral microinjection of [^3H]PGE $_2$. The peak of radioactivity was detected at the elution time of 8 min in all samples, and the sum of radioactivity eluted from 6 to 10 min, which was considered to correspond to intact PGE $_2$, was




Fig. 2. Typical HPLC chromatograms of [³H]PGE₂ in the injectate (A), ipsilateral cerebrum (B), and jugular venous plasma (C). An aliquot of [³H]PGE₂ (1 μCi) was injected into the S2 region of mouse brain. Ipsilateral cerebrum was removed at 5 min, and venous blood was collected from the ipsilateral jugular vein at 5 min after microinjection. HPLC analysis was performed at a flow rate of 1.0 ml/min. Each point represents the radioactivity measured in the corresponding fraction (1.0 ml/each).

90.7, 87.1, and 48.1% of the total radioactivity in the injectate, cerebrum, and plasma, respectively. This result suggests that [³H]PGE₂ in the cerebral cortex is predominantly transported in intact form to the circulation across the BBB.

***cis*-Inhibitory Effect of Drugs on MRP4-Mediated [³H]PGE₂ Transport.** MRP4 was considered to be involved in PGE₂ efflux transport from inside of brain capillary endothelial cells to circulating blood, and drugs inhibited MRP4-

mediated PGE₂ transport at the intracellular side, which is known as *cis*-inhibition. Thus, the *cis*-inhibitory effect of various drugs on MRP4-mediated PGE₂ transport was assessed by means of an uptake study using inside-out human MRP4-expressing membrane vesicles. The uptake of [³H]PGE₂ into MRP4-expressing membrane vesicles increased linearly for 10 min and was significantly greater than that into control vesicles (Fig. 3A). Cefmetazole is a selective substrate for human MRP4 with a *K_m* value of 28.5 μM and is not a substrate/inhibitor for other ATP-binding cassette transporters expressed at the BBB, such as P-glycoprotein (*ABCB1*) and rat breast cancer resistance protein (*ABCG2*) (Okumura et al., 2007; Uchida et al., 2007). The concentration-dependent inhibitory effect of cefmetazole on human MRP4-medi-




Fig. 3. Time profile of [³H]PGE₂ uptake (A) and concentration-dependent inhibitory effect of cefmetazole on [³H]PGE₂ uptake (B) into MRP4-expressing membrane vesicles. Membrane vesicles (5 μg) were incubated at 37°C in the uptake medium containing 20 nM [³H]PGE₂ and 4 mM ATP. A, [³H]PGE₂ uptake into MRP4-expressing Sf9 membrane vesicles (●) or control vesicles (mock, ○) was examined for the indicated time. B, [³H]PGE₂ uptake was measured for 5 min in the presence of cefmetazole at the indicated concentration. MRP4-mediated transport was obtained by subtracting the transport rate in mock from that in MRP4-expressing Sf9 membrane vesicles. The values are expressed as a percentage of the [³H]PGE₂ uptake mediated by MRP4 in the absence of cefmetazole. The solid line was obtained by means of nonlinear least-squares regression analysis. Each point represents the mean ± S.E.M. (*n* = 3).

ated [^3H]PGE₂ transport was examined at 5 min, and the IC₅₀ value was determined to be $10.2 \pm 3.2 \mu\text{M}$ (mean \pm S.D.) (Fig. 3B).

Inhibitory effects of drugs, including antibiotics and NSAIDs, were also examined at the concentration of $20 \mu\text{M}$ (Table 1). Among cephalosporins, cefazolin, cefotaxime, ceftriaxone, cefotiam, and cefdinir significantly inhibited MRP4-mediated [^3H]PGE₂ transport by more than 35%, whereas cephalixin, cefsulodin, and cefaclor did not. Other antibiotics and antifungals exhibited no effect. Among inhibitors of organic anion transporters, dipyridamole significantly inhibited MRP4-mediated [^3H]PGE₂ transport by 57%, whereas taurocholate and ursodeoxycholate were not inhibitory. Among NSAIDs, indomethacin strongly inhibited MRP4-mediated [^3H]PGE₂ transport by 81% and ibuprofen, ketoprofen, acetaminophen, and celecoxib significantly inhibited the transport by more than 30%, whereas salicylate, loxoprofen, mefenamic acid, diclofenac, sulpyrine, meloxicam, and ampiroxicam were not inhibitory.

Effect of Intracerebral Preadministration of Drugs on [^3H]PGE₂ Elimination from the Brain. The effect of drugs on [^3H]PGE₂ elimination from the brain across the

TABLE 1
Effect of various compounds at $20 \mu\text{M}$ on [^3H]PGE₂ uptake into MRP4-expressing membrane vesicles

Membrane vesicles ($5 \mu\text{g}$) were incubated at 37°C in the uptake medium containing 20 nM [^3H]PGE₂ and 4 mM ATP. [^3H]PGE₂ uptake was measured for 5 min in the presence of each inhibitor at the concentration of $20 \mu\text{M}$. MRP4-mediated transport was obtained by subtracting the transport rate in mock from that in MRP4-expressing S9 membrane vesicles. The values are expressed as a percentage of the [^3H]PGE₂ uptake mediated by MRP4 in the absence of inhibitors. Each value represents the mean \pm S.E.M.

Compound	No. Studied	%Control
Control	15	100 \pm 4
Antibiotics (cephems)		
Ceftriaxone	3	6.62 \pm 5.05**
Cefotaxime	3	34.5 \pm 6.4**
Cefdinir	3	36.1 \pm 3.3**
Cefotiam	3	59.0 \pm 3.8**
Cefazolin	3	63.2 \pm 3.3**
Cephalixin	3	109 \pm 3
Cefsulodin	3	106 \pm 2
Cefaclor	5	100 \pm 4
Other kinds of antibiotics		
Clarithromycin	3	79.6 \pm 6.6
Kanamycin	3	97.7 \pm 0.3
Minocycline	3	96.1 \pm 4.4
Vancomycin	3	113 \pm 7
Antifungals		
Amphotericin B	3	81.4 \pm 3.3
Itraconazole	3	111 \pm 9
Fluconazole	3	98.0 \pm 2.3
Miconazole	3	108 \pm 7
NSAIDs		
Indomethacin	3	18.9 \pm 1.8**
Ketoprofen	3	49.1 \pm 2.4**
Ibuprofen	3	53.3 \pm 2.6**
Celecoxib	3	62.4 \pm 4.4**
Acetaminophen	3	70.7 \pm 3.0**
Mefenamic acid	3	80.9 \pm 0.3
Loxoprofen	3	85.0 \pm 6.3
Sulpyrine	3	89.1 \pm 4.7
Salicylate	3	88.5 \pm 6.7
Meloxicam	3	94.2 \pm 4.9
Diclofenac	3	94.8 \pm 0.7
Ampiroxicam	3	103 \pm 2
Organic anion transporter inhibitors		
Dipyridamole	3	42.7 \pm 4.2**
Ursodeoxycholate	3	77.1 \pm 4.2
Taurocholate	3	101 \pm 2

** $p < 0.01$, significantly different from control.

BBB was investigated by preadministration into the brain. As shown in Table 2, cefmetazole, cefazolin, cefotaxime, ceftriaxone, and benzylpenicillin decreased the BEI values of [^3H]PGE₂ by 39, 32, 51, 39, and 29%, respectively, indicating that these drugs inhibited brain-to-blood efflux transport of [^3H]PGE₂ at the BBB. Cefotiam, cefsulodin, itraconazole, and clarithromycin had no significant effect. Among NSAIDs, indomethacin and ketoprofen decreased the BEI values of [^3H]PGE₂, whereas celecoxib did not. In addition, dipyridamole did not inhibit [^3H]PGE₂ efflux from brain across the BBB. The BEI value in the case of preadministration of ECF buffer with or without 0.25% DMSO was not significantly different from that in the case of no preadministration treatment (Fig. 1; Table 2).

Effect of Intravenous Administration of Drugs on [^3H]PGE₂ Elimination from the Brain. The inhibitory effect of intravenous administration of cefmetazole on [^3H]PGE₂ efflux at the BBB was examined to clarify the effect of cefmetazole in circulating blood on PGE₂ elimination (Fig. 4). The BEI value of [^3H]PGE₂ was significantly reduced by administration of 100, 200, and 1000 mg/kg cefmetazole, and the estimated ID₅₀ value was $120 \pm 18 \text{ mg/kg}$ (mean \pm S.D.).

Table 3 shows the inhibitory effect of intravenous administration of various drugs on [^3H]PGE₂ elimination from the brain. Among antibiotics, 200 mg/kg cefmetazole and 200 mg/kg cefazolin significantly reduced the BEI value of [^3H]PGE₂ by 25 and 19%, respectively. Cefotaxime, ceftriaxone, cephalixin, cefaclor, and cefsulodin had no significant effect at the dose of 200 mg/kg. In addition, 40 mg/kg dipyridamole significantly decreased the BEI value of [^3H]PGE₂ by 28%, whereas 10 and 100 mg/kg taurocholate, 100 mg/kg ursodeoxycholate, 20 mg/kg diclofenac, and 40 mg/kg ketoprofen had little effect (Table 3).

Discussion

The present study indicates that PGE₂ is eliminated from the mouse cerebral cortex via a carrier-mediated process at the BBB (Figs. 1 and 2). In addition, intracerebral and/or intravenous administration of cefmetazole and cefazolin, which inhibits MRP4-mediated [^3H]PGE₂ transport in vitro (Fig. 3; Table 1), reduces [^3H]PGE₂ efflux from brain across the BBB (Fig. 4; Tables 2 and 3).

Using the BEI method, it was shown that [^3H]PGE₂ injected into mouse cerebral cortex was eliminated with a half-life of 16.3 min and the elimination of [^3H]PGE₂ was inhibited by coadministration of unlabeled PGE₂ (Fig. 1). Moreover, [^3H]PGE₂ was suggested to cross the BBB predominantly in the intact form, because as much as 48.1% of the total ^3H radioactivity in the jugular venous plasma was found to be associated with intact PGE₂ (Fig. 2), and it has been reported that [^3H]PGE₂ in the circulating blood after systemic administration is extensively metabolized in 5 min in rats (Eguchi et al., 1992). The other radioactivity in the plasma could be due mainly to metabolites generated in peripheral tissues. Overall, it appears that the BBB plays a role in modulating the activity of PGE₂ through the elimination of intact PGE₂ from the brain interstitial fluid to circulating blood via a carrier-mediated process.

PGE₂ is a substrate of MRP4, Oat3, and Pgt, which were reported to be expressed at the BBB (Pucci et al., 1999; Reid et al., 2003; Nilwarangkoon et al., 2007). We recently found

TABLE 2

Effect of preadministration of various compounds at 5 mM on [³H]PGE₂ elimination from brain across the BBB in mice

Each compound or ECF buffer (control) was administered at 5 min before administration of [³H]PGE₂. Clarithromycin, itraconazole, indomethacin, ketoprofen, dipyridamole, or celecoxib was administered with ECF buffer containing 0.25% DMSO. As a control for these compounds, ECF buffer containing 0.25% DMSO was injected. The BEI value was determined 40 min after intracerebral microinjection of [³H]PGE₂. Each value represents the mean ± S.E.M.

Compound	No. Studied	BEI	%Control
%			
Antibiotics and antifungals			
Control	7	65.3 ± 1.6	100 ± 3
Cefmetazole	6	40.2 ± 3.2	61.5 ± 4.8**
Cefazolin	5	44.5 ± 4.3	68.2 ± 6.6**
Cefotaxime	3	32.0 ± 2.0	49.0 ± 3.0**
Ceftriaxone	4	39.9 ± 7.0	61.0 ± 10.7**
Benzylpenicillin	4	46.5 ± 4.7	71.2 ± 7.1**
Cefotiam	3	63.9 ± 4.7	97.9 ± 5.2
Cefsulodin	4	58.3 ± 3.4	89.3 ± 5.2
Control (0.25% DMSO)	8	62.6 ± 3.5	100 ± 6
Clarithromycin (0.25% DMSO)	5	55.3 ± 5.7	88.3 ± 9.1
Itraconazole (0.25% DMSO)	7	51.4 ± 3.8	82.1 ± 6.1
Inhibitors of organic anion transporters and NSAIDs			
Control (0.25% DMSO)	8	62.6 ± 3.5	100 ± 6
Indomethacin (0.25% DMSO)	3	13.0 ± 5.6	20.8 ± 9.0**
Ketoprofen (0.25% DMSO)	3	30.1 ± 4.4	48.1 ± 7.1**
Dipyridamole (0.25% DMSO)	3	61.4 ± 5.4	98.1 ± 8.6
Celecoxib (0.25% DMSO)	3	63.9 ± 5.7	102 ± 9

** $p < 0.01$, significantly different from control.




Fig. 4. Dose-dependent inhibitory effect of cefmetazole intravenous administration on [³H]PGE₂ elimination from mouse brain across the BBB. Various amounts of cefmetazole were administered intravenously 15 min before administration of [³H]PGE₂. The BEI value was determined 40 min after intracerebral microinjection of [³H]PGE₂. Each point represents the mean ± S.E.M. ($n = 3-4$). *, $p < 0.05$; **, $p < 0.01$, significantly different from control.

that the protein expression level of MRP4 in mouse brain capillaries is 10.3 to 12.5% of that of P-glycoprotein, 33.1 to 39.6% of that of breast cancer resistance protein, and similar to that of Oat3 protein (Kamiie et al., 2008). A preadministration study demonstrated that [³H]PGE₂ elimination from mouse brain was inhibited by cefmetazole, which is a high-affinity substrate for MRP4 (Table 2). In addition, [³H]PGE₂ was taken up into human MRP4-expressing membrane vesicles, and cefmetazole inhibited [³H]PGE₂ uptake into the vesicles with an IC₅₀ value of 10.2 μM (Fig. 3). This value is similar to the K_m value of human MRP4-mediated cefmetazole transport (Uchida et al., 2007). These results suggest that MRP4 is involved in the brain-to-blood efflux transport of [³H]PGE₂ at the BBB.

Oatp1a4 and Oat3 are involved in brain-to-blood efflux transport at the BBB, whereas Pgt is thought to be involved

in blood-to-brain influx transport (Kis et al., 2006; Ohtsuki and Terasaki, 2007). Cefmetazole was reported to be a substrate of rat Oatp1a4 (Nakakariya et al., 2008), but there is no report that PGE₂ is a substrate for Oatp1a4. Furthermore, cefotiam inhibits human Oat3-mediated estrone sulfate transport (IC₅₀ = 213 μM) and cefsulodin is a substrate for rat Oatp1a4 (Ueo et al., 2005; Nakakariya et al., 2008). Because the dilution effect of compounds at the microinjection site should have been minimal in this study, 5 mM cefotiam and cefsulodin injected in the brain should have been sufficient to inhibit Oat3 and Oatp1a4 at the BBB. However, in a preadministration study, cefotiam and cefsulodin did not inhibit [³H]PGE₂ elimination from brain across the BBB (Table 2), suggesting that Oat3 and Oatp1a4 do not play major roles in the brain-to-blood efflux transport of [³H]PGE₂ at the BBB.

At the BBB, MRP4 plays a role in excreting compounds from BCECs to circulating blood. To cause a *cis*-inhibitory effect on MRP4-mediated PGE₂ transport, drugs would have to be taken up from brain interstitial fluid and maintained at a high concentration in BCECs. Cefazolin, cefotaxime, ceftriaxone, and indomethacin inhibited MRP4-mediated [³H]PGE₂ accumulation in membrane vesicles, and preadministration of these drugs into the brain also decreased [³H]PGE₂ elimination from the brain (Table 2). In contrast, preadministration of cefotiam, dipyridamole, and celecoxib did not significantly decrease [³H]PGE₂ elimination (Table 2), although these drugs inhibited the uptake of [³H]PGE₂ into the membrane vesicles (Table 1). These differences in inhibitory effect may be due to differences in the uptake process from brain interstitial fluid into the BCECs.

It is important to clarify the effect of peripheral administration of drugs to understand drug interactions with [³H]PGE₂ elimination from the brain. Intravenous administration of cefmetazole inhibited the efflux from brain across the BBB with an ID₅₀ value of 120 mg/kg in mice (Fig. 4). Although the cefmetazole dosage (14.3–28.6 mg/kg) is lower in clinical cases, it is considered that cerebral PGE₂ elimination across the BBB may be inhibited by cefmetazole admin-

TABLE 3

Effect of intravenous administration of various compounds on [^3H]PGE₂ elimination from brain across the BBB in mice. Each compound or Ringer-HEPES buffer (control) was administered via the jugular vein at 15 min before administration of [^3H]PGE₂. The BEI value was determined 40 min after intracerebral microinjection of [^3H]PGE₂. Each value represents the mean \pm S.E.M.

Compound	Injected Amount	No. Studied	BEI	%Control
	<i>mg/kg</i>		<i>%</i>	
Control		18	66.7 \pm 2.0	100 \pm 3
Antibiotics (cephems)				
Cefmetazole	200	6	50.3 \pm 5.5	75.4 \pm 8.2**
Cefazolin	200	4	53.7 \pm 5.6	80.6 \pm 8.4*
Cefotaxime	200	4	76.4 \pm 2.7	115 \pm 4
Ceftriaxone	200	3	66.0 \pm 1.2	98.9 \pm 1.8
Cephalexin	200	4	70.2 \pm 1.9	105 \pm 3
Cefaclor	200	4	70.8 \pm 2.7	106 \pm 4
Cefsulodin	200	6	66.8 \pm 2.2	100 \pm 3
Inhibitors of organic anion transporters and NSAIDs				
Dipyridamole	40	4	47.8 \pm 12.4	71.6 \pm 18.6*
Taurocholate	10	5	60.2 \pm 5.6	90.3 \pm 8.5
	100	5	58.5 \pm 5.1	87.7 \pm 7.6
Ursodeoxycholate	100	4	64.7 \pm 5.8	97.1 \pm 8.7
Ketoprofen	40	4	66.5 \pm 5.3	99.7 \pm 7.9
Diclofenac	20	4	74.4 \pm 4.7	111 \pm 7.1

* $p < 0.05$; ** $p < 0.01$, significantly different from control.

istration in humans, because total body clearance of cefmetazole in humans (approximately 1.46 ml/min/kg) is lower than that in mice (approximately 26.2 ml/min/kg) (Shindo et al., 1978; Komiya et al., 1981; Ko et al., 1989). Moreover, in patients with renal failure who receive cefmetazole, there is a decline of total body clearance and the concentration of cefmetazole remains high (Tajima et al., 2006). Under this condition, it is possible that a high plasma concentration of cefmetazole would reduce [^3H]PGE₂ efflux from brain and aggravate excitatory and inflammatory responses, such as fever and seizure.

Intravenous administration of cefazolin also inhibited [^3H]PGE₂ efflux from brain across the BBB (Table 3). Cefazolin and cefmetazole are substrates of rat Oatp1a4, whereas cefotaxime, ceftriaxone, and ketoprofen are not (Nakakariya et al., 2008). Oatp1a4 has been reported to be localized at the abluminal and luminal membranes of rat BBB and to be involved in transport in both directions at the BBB (Gao et al., 1999). Therefore, cefazolin and cefmetazole are likely to be concentratedly taken up into BCECs via Oatp1a4 at the luminal membrane of the BBB, leading to *cis*-inhibition of MRP4-mediated PGE₂ transport at the luminal membrane of the BBB. On the other hand, intravenous administration of cefotaxime, ceftriaxone, and ketoprofen, which have not been identified as Oatp1a4 substrates, had little effect on [^3H]PGE₂ elimination from the brain (Table 3), even though intracerebral preadministration of these drugs inhibited [^3H]PGE₂ efflux transport (Table 2). This may be because their concentrations in the BCECs were not sufficiently high to inhibit the MRP4-mediated [^3H]PGE₂ transport, because of the lack of a transport process for these drugs at the luminal membrane of BCECs.

The [^3H]PGE₂ elimination from brain across the BBB was inhibited by intravenous administration of dipyridamole (Table 3). In vitro MRP4-mediated [^3H]PGE₂ transport was strongly inhibited by dipyridamole (Table 1). However, dipyridamole did not inhibit [^3H]PGE₂ elimination in a preadministration study (Table 2). It is possible that the blood-to-cell transport process for dipyridamole is different from the brain-to-cell transport process at the BBB, although the mechanism(s) remains to be established.

Antibiotics and NSAIDs are administered peripherally for the remediation and palliative treatment of infectious and inflammatory conditions. It is known that β -lactam antibiotics, including cefmetazole and cefazolin, inhibit the GABA_A receptor response in rat cerebral cortex and cause seizure (Schliamser et al., 1991; Fujimoto et al., 1995). PGE₂ in the brain enhances excitatory neuronal response and induces a pain response (Oliveira et al., 2009). In addition, the brain concentration of PGE₂ is increased in inflammation induced by endotoxin administration (Inoue et al., 2002). Because PGE₂ elimination from brain across the BBB is inhibited by cefmetazole or cefazolin administration (Tables 2 and 3), the concentration of PGE₂ in the brain might be increased and the increased level of PGE₂ might have an additive or synergistic effect on the neuroexcitatory response. Moreover, many studies have attested to the importance of brain PGE₂, including COX function, in the development of neurodegenerative diseases, such as Alzheimer's disease (Takadera et al., 2002; Hoshino et al., 2007), and the PGE₂ concentration in cerebrospinal fluid is increased under these conditions (Montine et al., 1999). The present study has shown that PGE₂ in the brain is eliminated across the BBB and the elimination process could serve to control PGE₂ activity (Fig. 1). Hence, drugs that do not inhibit PGE₂ elimination from brain might be more appropriate for the treatment of these diseases, and assessment of the inhibitory effect on MRP4-mediated PGE₂ transport could be a valuable tool in drug development.

In conclusion, this study has provided the first evidence that PGE₂ in mouse brain is eliminated by a carrier-mediated process at the BBB and that MRP4 is involved in this elimination. Furthermore, intravenous administration of cefmetazole, cefazolin, and dipyridamole inhibited the elimination and might therefore affect central nervous system function via a resulting increase in the brain level of PGE₂. To ensure that drugs have no adverse effect in inflammatory and infectious diseases associated with high levels of PGE₂, it may be necessary to assess their inhibitory effect on PGE₂ transport mediated by MRP4.

Acknowledgments

We thank Yasuo Uchida for valuable discussions.

References

- Akanuma S, Ohtsuki S, Doi Y, Tachikawa M, Ito S, Hori S, Asashima T, Hashimoto T, Yamada K, Ueda K, et al. (2008) ATP-binding cassette transporter A1 (ABCA1) deficiency does not attenuate the brain-to-blood efflux transport of human amyloid- β peptide (1–40) at the blood-brain barrier. *Neurochem Int* **52**:956–961.
- Alix E, Schmitt C, Strazielle N, and Ghersi-Egea JF (2008) Prostaglandin E₂ metabolism in rat brain: Role of the blood-brain interfaces. *Cerebrospinal Fluid Res* **5**:5.
- Chen C and Bazan NG (2005) Endogenous PGE₂ regulates membrane excitability and synaptic transmission in hippocampal CA1 pyramidal neurons. *J Neurophysiol* **93**:929–941.
- Eguchi N, Kaneko T, Urade Y, Hayashi H, and Hayaishi O (1992) Permeability of brain structures and other peripheral tissues to prostaglandins D₂, E₂ and F_{2 α} in rats. *J Pharmacol Exp Ther* **262**:1110–1120.
- El-Sheikh AA, van den Heuvel JJ, Koenderink JB, and Russel FG (2007) Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. *J Pharmacol Exp Ther* **320**:229–235.
- Fujimoto M, Munakata M, and Akaie N (1995) Dual mechanisms of GABA_A response inhibition by β -lactam antibiotics in the pyramidal neurones of the rat cerebral cortex. *Br J Pharmacol* **116**:3014–3020.
- Gao B, Stieger B, Noé B, Fritschy JM, and Meier PJ (1999) Localization of the organic anion transporting polypeptide 2 (Oatp2) in capillary endothelium and choroid plexus epithelium of rat brain. *J Histochem Cytochem* **47**:1255–1264.
- Hoshino T, Nakaya T, Homan T, Tanaka K, Sugimoto Y, Araki W, Narita M, Narumiya S, Suzuki T, and Mizushima T (2007) Involvement of prostaglandin E₂ in production of amyloid- β peptides both in vitro and in vivo. *J Biol Chem* **282**:32676–32688.
- Ikedate-Matsuo Y, Ikegaya Y, Matsuki N, Uematsu S, Akira S, and Sasaki Y (2005) Microglia-specific expression of microsomal prostaglandin E₂ synthase-1 contributes to lipopolysaccharide-induced prostaglandin E₂ production. *J Neurochem* **94**:1546–1558.
- Inoue W, Matsumura K, Yamagata K, Takemiya T, Shiraki T, and Kobayashi S (2002) Brain-specific endothelial induction of prostaglandin E₂ synthesis enzymes and its temporal relation to fever. *Neurosci Res* **44**:51–61.
- Ivanov AI and Romanovsky AA (2004) Prostaglandin E₂ as a mediator of fever: synthesis and catabolism. *Front Biosci* **9**:1977–1993.
- Kakee A, Terasaki T, and Sugiyama Y (1996) Brain efflux index as a novel method of analyzing efflux transport at the blood-brain barrier. *J Pharmacol Exp Ther* **277**:1550–1559.
- Kamiie J, Ohtsuki S, Iwase R, Ohmine K, Katsukura Y, Yanai K, Sekine Y, Uchida Y, Ito S, and Terasaki T (2008) Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in-silico peptide selection criteria. *Pharm Res* **25**:1469–1483.
- Kim SY, Chang YJ, Cho HM, Hwang YW, and Moon YS (2009) Non-steroidal anti-inflammatory drugs for the common cold. *Cochrane Database Syst Rev* **3**:CD006362.
- Kimura H, Takeda M, Narikawa S, Enomoto A, Ichida K, and Endou H (2002) Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. *J Pharmacol Exp Ther* **301**:293–298.
- Kis B, Isse T, Snipes JA, Chen L, Yamashita H, Ueta Y, and Busija DW (2006) Effects of LPS stimulation on the expression of prostaglandin carriers in the cells of the blood-brain and blood-cerebrospinal fluid barriers. *J Appl Physiol* **100**:1392–1399.
- Ko H, Cathcart KS, Griffith DL, Peters GR, and Adams WJ (1989) Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination. *Antimicrob Agents Chemother* **33**:356–361.
- Kobayashi Y, Ohshiro N, Tsuchiya A, Kohyama N, Ohbayashi M, and Yamamoto T (2004) Renal transport of organic compounds mediated by mouse organic anion transporter 3 (mOat3): further substrate specificity of mOat3. *Drug Metab Dispos* **32**:479–483.
- Komiya M, Kikuchi Y, Tachibana A, and Yano K (1981) Pharmacokinetics of new broad-spectrum cephalosporins, YM09330, parenterally administered to various experimental animals. *Antimicrob Agents Chemother* **20**:176–183.
- Leggias M, Adachi M, Scheffer GL, Sun D, Wielinga P, Du G, Mercer KE, Zhuang Y, Panetta JC, Johnston B, et al. (2004) MRP4 confers resistance to topotecan and protects the brain from chemotherapy. *Mol Cell Biol* **24**:7612–7621.
- Molavi A (1991) Cephalosporins: rationale for clinical use. *Am Fam Physician* **43**:937–948.
- Montine TJ, Sidell KR, Crews BC, Markesbery WR, Marnett LJ, Roberts LJ 2nd, and Morrow JD (1999) Elevated CSF prostaglandin E₂ levels in patients with probable AD. *Neurology* **53**:1495–1498.
- Nakakariya M, Shimada T, Irokawa M, Koibuchi H, Iwanaga T, Yabuuchi H, Maeda T, and Tamai I (2008) Predominant contribution of rat organic anion transporting polypeptide-2 (Oatp2) to hepatic uptake of β -lactam antibiotics. *Pharm Res* **25**:578–585.
- Nakano J, Prancan AV, and Moore SE (1972) Metabolism of prostaglandin E₁ in the cerebral cortex and cerebellum of the dog and rat. *Brain Res* **39**:545–548.
- Nilwarangkoon S, Anzai N, Shiraya K, Yu E, Islam R, Cha SH, Onozato ML, Miura D, Jutabha P, Tojo A, et al. (2007) Role of mouse organic anion transporter 3 (mOat3) as a basolateral prostaglandin E₂ transport pathway. *J Pharmacol Sci* **103**:48–55.
- Nozaki Y, Kusuhara H, Kondo T, Iwaki M, Shiroyanagi Y, Nakayama H, Horita S, Nakazawa H, Okano T, and Sugiyama Y (2007) Species difference in the inhibitory effect of nonsteroidal anti-inflammatory drugs on the uptake of methotrexate by human kidney slices. *J Pharmacol Exp Ther* **322**:1162–1170.
- Ohtsuki S and Terasaki T (2007) Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain: importance for CNS drug discovery and development. *Pharm Res* **24**:1745–1758.
- Okumura H, Katoh M, Sawada T, Nakajima M, Soeno Y, Yabuuchi H, Ikeda T, Tateno C, Yoshizato K, and Yokoi T (2007) Humanization of excretory pathway in chimeric mice with humanized liver. *Toxicol Sci* **97**:533–538.
- Oliveira MS, Furian AF, Rambo LM, Ribeiro LR, Royes LF, Ferreira J, Calixto JB, Otalora LF, Garrido-Sanabria ER, and Mello CF (2009) Prostaglandin E₂ modulates Na⁺,K⁺-ATPase activity in rat hippocampus: implications for neurological diseases. *J Neurochem* **109**:416–426.
- Phillis JW, Horrocks LA, and Farooqui AA (2006) Cyclooxygenases, lipoxygenases, and epoxigenases in CNS: their role and involvement in neurological disorders. *Brain Res Rev* **52**:201–243.
- Pucci ML, Bao Y, Chan B, Itoh S, Lu R, Copeland NG, Gilbert DJ, Jenkins NA, and Schuster VL (1999) Cloning of mouse prostaglandin transporter PGT cDNA: species-specific substrate affinities. *Am J Physiol* **277**:R734–R741.
- Reid G, Wielinga P, Zelcer N, van der Heijden I, Kuil A, de Haas M, Wijnholds J, and Borst P (2003) The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal anti-inflammatory drugs. *Proc Natl Acad Sci USA* **100**:9244–9249.
- Schliamser SE, Cars O, and Norrby SR (1991) Neurotoxicity of β -lactam antibiotics: predisposing factors and pathogenesis. *J Antimicrob Chemother* **27**:405–425.
- Shindo H, Kawai K, Maeda T, Igarashi I, Tajima T, and Sugawara S (1978) Absorption, distribution, excretion and metabolism of a new cephalosporin antibiotic, CS-1170, in various animal species. *Chemotherapy (Tokyo)* **26**:99–114.
- Sugimoto Y and Narumiya S (2007) Prostaglandin E receptors. *J Biol Chem* **282**:11613–11617.
- Sunden Y, Park CH, Matsuda K, Anagawa A, Kimura T, Ochiai K, Kida H, and Umemura T (2003) The effects of antipyretics on influenza virus encephalitis in mice and chicks. *J Vet Med Sci* **65**:1185–1188.
- Tajima N, Nagashima S, Uematsu T, Torii H, Tajima M, Hishida A, and Naganuma H (2006) Prediction of pharmacokinetics of antibiotics in patients with end-stage renal disease. *Biol Pharm Bull* **29**:1454–1459.
- Takadera T, Yumoto H, Tozuka Y, and Ohyashiki T (2002) Prostaglandin E₂ induces caspase-dependent apoptosis in rat cortical cells. *Neurosci Lett* **317**:61–64.
- Uchida Y, Kamiie J, Ohtsuki S, and Terasaki T (2007) Multichannel liquid chromatography-tandem mass spectrometry cocktail method for comprehensive substrate characterization of multidrug resistance-associated protein 4 transporter. *Pharm Res* **24**:2281–2296.
- Ueo H, Motohashi H, Katsura T, and Inui K (2005) Human organic anion transporter hOAT3 is a potent transporter of cephalosporin antibiotics, in comparison with hOAT1. *Biochem Pharmacol* **70**:1104–1113.

Address correspondence to: Dr. Tetsuya Terasaki, Division of Membrane Transport and Drug Targeting, Graduate School of Pharmaceutical Sciences, Tohoku University, 6-3 Aoba, Aramaki, Aoba-ku, Sendai, Miyagi 980-8578, Japan. E-mail: terasaki@mail.pharm.tohoku.ac.jp